Latest Novartis Stories

LUND, Sweden, March 11, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, announces it has completed the acquisition of a portfolio of novel cyclophilin inhibitors, technology platform assets and related intellectual property rights from the UK biotech company Biotica Ltd. The acquisition of these assets is important strategically as it will allow NeuroVive to broaden and deepen its pipeline of novel mitochondrial medicines. No financial details of the...

PARSIPPANY, N.J., March 8, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed with the U.S. Food and Drug Administration (FDA) an amendment to its Abbreviated New Drug Application (ANDA) for Rivastigmine Transdermal System to include the 13.3 mg per 24 hours dosage strength. Actavis' ANDA product is a generic version of Novartis' Exelon(®) Patch, which is a prescription medicine used to treat people with mild to moderate dementia associated with...

NEW YORK, March 7, 2013 /PRNewswire/ -- Today, Investors Alliance announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Novartis AG (NYSE: NVS), and GlaxoSmithKline Plc (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Johnson & Johnson Research Report Since the...

Regeneron receives 4% to 15% royalty on sales of Ilaris TARRYTOWN, N.Y., March 4, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will receive an additional potential royalty stream now that the European Commission (EC) has approved Novartis' llaris (canakinumab, ACZ885) in the treatment of patients with acute gouty arthritis who suffer frequent attacks, and whose symptoms cannot or should not be managed with current treatment options....

- Approval sets new standard for corn rootworm control BASEL, Switzerland, Feb. 28, 2013 /PRNewswire/ -- Syngenta announced today that the United States Department of Agriculture (USDA) has fully deregulated Agrisure(®) Duracade(TM), enabling launch in the US for the 2014 planting season. Agrisure Duracade expresses a unique protein to control corn rootworm. It has a different mode of action to Syngenta's existing Agrisure(®) RW trait. When combined these traits provide...

Brings Extensive Leadership And Operations Experience in Healthcare Industry MALVERN, Pa., Feb. 25, 2013 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) today announced that Rajiv De Silva, a pharmaceutical executive who had been President of Valeant Pharmaceuticals and a senior executive at Novartis, has been named Endo's President and Chief Executive Officer, effective March 18. Mr. De Silva, who will also join the Endo Board of Directors, succeeds David Holveck who is...

CHICAGO, Feb. 21, 2013 /PRNewswire/ -- Zacks Equity Research highlights Valmont Industries (NYSE:VMI) as the Bull of the Day and Quest Diagnostics (NYSE:DGX) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Novartis (NYSE:NVS), Abbott (NYSE:ABT) and Eli Lilly (NYSE:LLY). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Full analysis of all these stocks is available at http://at.zacks.com/?id=2678. Here is a synopsis of all five stocks:...

BASEL, Switzerland, Feb. 15, 2013 /PRNewswire/ -- Syngenta announced that the 2012 Annual Report on Form 20-F has been filed with the U.S. Securities and Exchange Commission. The document is available on the Syngenta website at www.syngenta.com in the Investor Relations section; hard copies of the audited financial statements are available to shareholders free of charge upon request. Syngenta is one of the world's leading companies with more than 27,000 employees in over 90...

BASEL, Switzerland, Feb. 15, 2013 /PRNewswire/ -- Syngenta today requested that the European Commission retract its proposal to restrict the use of neonicotinoid technology after revealing that the European Food Safety Authority's (EFSA) report on the risks to bees from their use was fundamentally flawed. Syngenta submitted a response to the EFSA report in January. This showed that EFSA failed to consider key information proving the safety of thiamethoxam seed treatment for use on...

REDWOOD CITY, Calif., Feb. 12, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of Adrian Adams, Chief Executive Officer and President of Auxilium Pharmaceuticals, Inc., to its Board of Directors (Board) as Chairman of the Board. Thomas Schreck, co-founder of AcelRx and Board...